The most common activating EGFR alterations in non-small cell lung carcinoma (NSCLC) are somatic in-frame deletions within exon 19 and the L858R missense mutation in exon 21, together comprising 80–90% of activating EGFR mutations2,3. Here, EGFR is linked to non-small cell lung carcinoma.